DK0870197T3 - Anvendelse af nuclear magnetisk resonans til design af ligander rettet mod biomolekyler - Google Patents

Anvendelse af nuclear magnetisk resonans til design af ligander rettet mod biomolekyler

Info

Publication number
DK0870197T3
DK0870197T3 DK96939709T DK96939709T DK0870197T3 DK 0870197 T3 DK0870197 T3 DK 0870197T3 DK 96939709 T DK96939709 T DK 96939709T DK 96939709 T DK96939709 T DK 96939709T DK 0870197 T3 DK0870197 T3 DK 0870197T3
Authority
DK
Denmark
Prior art keywords
target molecule
ligands
design
magnetic resonance
nuclear magnetic
Prior art date
Application number
DK96939709T
Other languages
English (en)
Other versions
DK0870197T4 (da
Inventor
Stephen W Fesik
Philip J Hajduk
Edward T Olejniczak
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27415774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0870197(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/558,633 external-priority patent/US5891643A/en
Priority claimed from US08/744,701 external-priority patent/US5989827A/en
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0870197T3 publication Critical patent/DK0870197T3/da
Publication of DK0870197T4 publication Critical patent/DK0870197T4/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4633—Sequences for multi-dimensional NMR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK96939709T 1995-11-14 1996-11-13 Anvendelse af nuclear magnetisk resonans til design af ligander rettet mod biomolekyler DK0870197T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/558,633 US5891643A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to design ligands to target biomolecules
US67890396A 1996-07-12 1996-07-12
US08/744,701 US5989827A (en) 1995-11-14 1996-10-31 Use of nuclear magnetic resonance to design ligands to target biomolecules
PCT/US1996/018312 WO1997018469A2 (en) 1995-11-14 1996-11-13 Use of nuclear magnetic resonance to design ligands to target biomolecules

Publications (2)

Publication Number Publication Date
DK0870197T3 true DK0870197T3 (da) 2001-08-27
DK0870197T4 DK0870197T4 (da) 2007-02-26

Family

ID=27415774

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96939709T DK0870197T4 (da) 1995-11-14 1996-11-13 Anvendelse af nuclear magnetisk resonans til design af ligander rettet mod biomolekyler

Country Status (12)

Country Link
EP (1) EP0870197B2 (da)
JP (1) JP3300366B2 (da)
AT (1) ATE201768T1 (da)
AU (1) AU711092B2 (da)
DE (1) DE69613146T3 (da)
DK (1) DK0870197T4 (da)
ES (1) ES2159056T5 (da)
GR (1) GR3036454T3 (da)
IL (1) IL123572A (da)
MX (1) MX9803805A (da)
PT (1) PT870197E (da)
WO (1) WO1997018469A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
WO2000005414A1 (en) * 1998-07-21 2000-02-03 Rutgers, The State University Linking gene sequence to gene function by three dimensional (3d) protein structure determination
US6333149B1 (en) * 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
MXPA02008253A (es) * 2000-02-25 2002-11-29 Wyeth Corp Metodos de diseno de farmacos basados en la estructura usando em/rmn.
JP5129424B2 (ja) 2000-09-27 2013-01-30 ユニヴェルシテイト レイデン リガンドの発見または薬物スクリーニング手段としてのｎｍｒ利用法
US7653490B2 (en) 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
NO20025738D0 (no) * 2002-11-29 2002-11-29 Amersham Health As Metode
JP4192078B2 (ja) 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
US20080293150A1 (en) * 2004-02-02 2008-11-27 Toshiyuki Kohno Nmr Signal Assignment Method
US20090239760A1 (en) 2006-03-14 2009-09-24 University Of Basel Method for the Identification of New Leads for Drug Candidates
KR20200057071A (ko) * 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물
WO2020260277A1 (en) * 2019-06-25 2020-12-30 Albert-Ludwig-Universität Freiburg Method and kit for measuring of analytes in bi-component systems and uses thereof
CN117912601B (zh) * 2024-01-26 2024-11-01 苏州腾迈医药科技有限公司 分子构象的展示方法及装置、介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7034791A (en) * 1989-12-29 1991-07-24 University Technologies International Inc. Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5393669A (en) * 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US8558663B2 (en) † 2007-11-30 2013-10-15 Bank Of America Corporation Integration of facial recognition into cross channel authentication
DE102008042959A1 (de) † 2008-10-20 2010-04-22 Zf Friedrichshafen Ag Verfahren zur Steuerung eines Kraftfahrzeug-Antriebsstrangs
US8678903B1 (en) † 2012-09-13 2014-03-25 Chia-Yen Lin Mobile device having a virtual spin wheel and virtual spin wheel control method of the same

Also Published As

Publication number Publication date
PT870197E (pt) 2001-11-30
AU711092B2 (en) 1999-10-07
AU7680496A (en) 1997-06-05
JP3300366B2 (ja) 2002-07-08
ES2159056T3 (es) 2001-09-16
WO1997018469A3 (en) 1997-08-07
JP2002510384A (ja) 2002-04-02
IL123572A0 (en) 1998-10-30
DE69613146T2 (de) 2003-01-16
DK0870197T4 (da) 2007-02-26
GR3036454T3 (en) 2001-11-30
EP0870197B1 (en) 2001-05-30
MX9803805A (es) 1998-09-30
DE69613146T3 (de) 2007-06-14
DE69613146D1 (de) 2001-07-05
EP0870197A2 (en) 1998-10-14
EP0870197B2 (en) 2006-11-08
WO1997018469A2 (en) 1997-05-22
ES2159056T5 (es) 2007-07-16
ATE201768T1 (de) 2001-06-15
IL123572A (en) 2004-06-01

Similar Documents

Publication Publication Date Title
DK0866967T3 (da) Anvendelse af kernemagnetisk resonans til identifikation af ligander til mål-biomolekyler
DK0870197T4 (da) Anvendelse af nuclear magnetisk resonans til design af ligander rettet mod biomolekyler
CA2653517A1 (en) Process of designing a drug
CA2286795A1 (en) Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
DK0839152T3 (da) Kombinatoriske biblioteker af mærkede, biokemiske forbindelser og fremgangsmåde til fremstilling af disse
Brechbiel et al. Preparation of the Novel Chelating Agent N-(2-Aminoethyl)-trans-1, 2-diaminocyclohexane-N, N ‘, N ‘‘-pentaacetic Acid (H5CyDTPA), a Preorganized Analogue of Diethylenetriaminepentaacetic Acid (H5DTPA), and the Structures of BiIII (CyDTPA) 2-and BiIII (H2DTPA) Complexes
ATE216777T1 (de) Affinitäts-selektion von liganden mittels massenspektroskopie
Wilbur et al. Biotin reagents for antibody pretargeting. 2. Synthesis and in vitro evaluation of biotin dimers and trimers for cross-linking of streptavidin
Reveco et al. Study of a cyclometalated complex of ruthenium by 400-MHz two-dimensional proton NMR
Pregosin et al. 2-D NMR Spectroscopy of chiral phosphine complexes. Applications to problems related to enantioselective homogeneous catalysis
Jha et al. Arylation of Secondary Phosphines with Diaryliodonium Salts under Metal‐Free and Non‐Photochemical Conditions
Cénac et al. Zirconium-Promoted Ring Opening. Scope and Limitations
JP2003513290A (ja) ターゲット生体分子と相互作用するリガンドの同定のための二量子１ｈ−ｎｍｒスペクトロスコピーの使用
Kumar et al. Synthesis and selectivity in the formation of cyclophosphazene-derived 1, 3-cyclohexadienes from reactions of RCpCo (COD)[R= MeOC (O)] with alkynes and alkenes
Juarez-Garcia et al. Combined Moessbauer and EPR studies of the S= 3 state of an exchange-coupled iron (III)-copper (II) complex: test for quantitative EPR analysis of integer spin systems
Qian et al. Synthesis and Structure of Li [(C5H4) CH2CH2 (TACN-i Pr2)]. A Lithium Complex Supported by a Cp/TACN-i Pr2 Ligand
Nakazawa et al. Migration of the phosphorus ligand from iron to the cyclopentadienyl ring in complexes of the type (. eta. 5-C5H5)(CO) LFe {P (O) YZ}
Chatt et al. Preparation and properties of complexes of osmium (II) with carbonyl, nitrosyl, organic cyanide and organic isocyanide ligands
Ikura et al. Two-dimensional double-quantum coherence echo correlated spectroscopy in proton NMR
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
GRIMES Metallacarborane-based precursors for electroactive materials(Final Report, 1 Jun. 1992- 31 May 1995)
Mashuta et al. Binuclear schiff base complexes
Bray Metal ions in biological systems, volume 22. ENDOR, EPR, and electron spinnecho for probing coordination spheres: Edited by Helmut Sigel. 1987. 328 pages, bound, illustrated. $89.75 (US and Canada); $107.50 (All other countries).
LLOYD-JONES NUCLEAR MAGNETIC RESONANCE STUDIES OF CHROMIUM AND GROUP VB COMPOUNDS (NMR)
Somsook NMR-based solution structures and mechanisms of metallocene olefin polymerization catalysis